LEVERAGING SCIENCE TO PROVIDE PERSONALIZED CANNABINOID BASED THERAPEUTIC CANCER TREATMENTS
Cannabics Pharmaceuticals Inc. (CNBX) is a U.S public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and Cancer.
ADDRESSING THE MARKET NEED FOR PERSONALIZED, PRECISE MEDICINE
Holds a Ph.D. in Neurophysiology, Brain Waves and Cortical Connectivity in Attention. After obtaining his Ph.D. he was an entrepreneur in the field of neurofeedback and developed “Luna Mind” – recreational brain-computer interfaces. Dr. Ballan holds an M.Sc. from Tel-Aviv University – Magna Cum Laude – in molecular biology and anticancer drug development. Dr. Ballan was part of the research team which developed Salirasib (Treatment for Non-Small Cell Lung Cancer).
Since 2005 Eyal has been teaching the “Second Attention”- Neuro-Physiological aspects of Higher Perception and Cognition.
Core member of Cannabics’s founding team. Prior to becoming CEO at Cannabics, Mr. Barad spent years in the online media world, taking part in many different ventures and businesses. Alongside serving as the CEO of a digital media company for over 13 years, Mr. Barad also participated in other business collaborations in many different areas including, but not limited to, the development and use of big-data and Artificial Intelligence to develop predictive models for decision making processes.
Eyal has a BA in Economics & International Relations from the Hebrew University in Jerusalem and an MBA with Honors from Haifa University.
Dr. Sharir is widely recognized for her role in identifying a potentially new cannabinoid receptor, GPR55. She was a member of a research group responsible for discovering that human GPR55 is activated by several types of cannabinoids. Dr. Sharir has published nine peer-reviewed research papers on the topic. The research was funded by the National Institute of Health (NIH/NIDA), and results are available through the National Center for Biotechnology Information (NCBI).
Dr. Sharir is also proficient in the development, optimization and implementation of high-throughput screening (HTS) and high-content screening (HCS) assessments – approaches to cell biology that are used for large-scale applications.
Took the company public on the US exchange and is a native Washingtonian. David brings a dynamic and
varied background, having worked in the Diplomatic Corps in the Israeli Foreign Office as well as
a Congressional Aide in the US Congress, and General Counsel to consultants at the World Bank as well as the IDB, EX-IM and IMF in Washington, DC. He has a BA in International Relations from the University of Maryland, and JD from Antioch DC School of Law.
With extensive experience in digital media and medical cannabis, Mr. Permont serves as the company’s VP of Business Development, and also oversees the company’s PR and IR Activities.
Mr. Permont also served as Communication Director and Patient Instructor at Israel’s first Licensed Cannabis Producer for a period of 7 years.
Has over 20 years of broad experience in
corporate finance, accounting, M&A transactions, IPO’s and operations. Mr. Ben-Or is CEO & Founder of one of the few financial firms in Israel to have the International Standard on Assurance Engagement (ISAE 3402/SAS 70 Type II) assurance with control compliances, the new global standard for assurance reporting. He previously served as an Auditor at PricewaterhouseCoopers Accounting Firm.
Mr. Ben-Or holds a BA degree in Business from the College of Administration, an MBA degree from the Bar Ilan University and is a Certified Public Accountant.
BOARD OF ADVISORS
Dr. Feiler is a banker and hedge fund manager. Dr. Feiler served as Board Member of Advanced Vision Technology, traded on the Frankfurt Stock Exchange (VSJ), served on the Board of Safra Bank Mutual Fund Division; and has served as Administrative advisor for the Government of Ras Al Khaimah, UAE. Dr. Feiler has published extensively on business opportunities and strategies and was a frequent speaker in world events including the World Economic Forum in Davos
Estery Giloz-Ran is a PhD and CPA who has over a decade specializing in multi-national business development. Dr Gilon-Raz served as head of grants capital investment law, at INTEL Corporation, Israel. She is past Chairman of the Board of Tamir Fishman, a venture capital firm; has been external director in eight significant public companies such as KAMADA (KMDA); Director at Emerald, a medical device company; lecturer at Bar Ilan University, Ben Gurion University; and visiting professor at the Stern Business School (New York).
Dr. Mofkadi holds a Ph.D in Financial Economics from Tel Aviv University. He is a lecturer at Tel Aviv University, the Interdisciplinary Center in Herzliya and universities abroad. He is the author of ‘The Handbook of Corporate Valuation’. Dr. Mofkadi provides expert opinions in financing, economic, and legal proceedings, writing valuations and optimal pricing policies as well as economic analysis of competition and regulatory aspects, risk assessment and more.
Prof. Amos Toren is the Director of Pediatric Hemato-Oncology and BMT Department at the Sheba Medical Center since 2001 and a Professor in the division of Hematology, Sackler School of Medicine Tel-Aviv University. Prof. Toren is a specialist in Pediatrics, General Hematology and Pediatric Hemato-Oncology. He also has a PhD degree in genetics and qualified as a Master of Health Administration (MHA) at the Recannati Business School, Tel-Aviv University. Professor Toren runs numerous clinical studies, investigator initiated, company initiated, unicenter as well as multicenter.
Dr. Sigalit Ariely-Portnoy has vast experience in the pharmaceutical industry and managed pharmaceutical and chemical plants at Taro pharmaceutical industries Ltd as Operation Group Vice President and in Teva Pharmaceutical Industries Ltd as OSD plant manager. In the last 7 years, Sigalit is the CEO of Gsap, the largest consulting company for pharmaceutical and medical device companies in Israel. Sigalit Ariely-Portnoy has a BSc and PhD in Chemical Engineering and MSc in Bio-Medical Engineering from the Technion – Israel Institute of Technology, Haifa, Israel.